Merck Says Pembrolizumab Reduces Progression, Death Risk 43% in Certain Advanced Endometrial Cancer Patients

What happened

Merck said its drug pembrolizumab, sold as Keytruda, reduced the risk of disease progression or death by 43% versus chemotherapy in certain patients with advanced or recurrent endometrial cancer with dMMR tumors. Median progression-free survival was 38.2 months versus 8.4 months for chemotherapy.

Confirmed

Global impact / market context

A 43% reduction in progression or death risk could support wider use of Keytruda in this cancer type, which may lift Merck's oncology revenue. Still, the article gives no sales forecast, regulatory filing plan, or price, so the financial benefit is not yet quantified.

Analyst inference

The trial, called KEYNOTE-C93, is described as the first Phase 3 PD-1 inhibitor trial to show significant progression-free survival improvement as a standalone therapy. That positions Keytruda against platinum doublet chemotherapy, but without approval, pricing, or competitor data, the commercial impact remains uncertain.

Analyst inference

What to watch

1. Merck reported a favorable trend in overall survival for pembrolizumab monotherapy versus platinum doublet chemotherapy, but the article does not give a numerical survival benefit or say whether it was statistically significant. Confirmed
2. Watch whether Merck files for regulatory approval in this dMMR endometrial cancer setting, since approval would be needed before the trial result can translate into wider prescribing and revenue. Proposed
3. Track whether hospitals and payers adopt pembrolizumab as a first treatment option over chemotherapy, because treatment guidelines and reimbursement decisions would shape actual patient use and Merck's sales. Analyst inference

Evidence

• Original source link unavailable